Table 1 Demographic and Baseline Characteristics (Full Analysis Set)
Monotherapy (Part A) N = 25 | Combination therapy (Pat B) N = 46 | |
|---|---|---|
Age (years) | ||
Median (min-max) | 45 (26–70) | 36 (19–68) |
< 60, n (%) | 19 (76.0) | 43 (93.5) |
≥ 60, n (%) | 6 (24.0) | 3 (6.5) |
Sexa, n (%) | ||
Female | 11 (44.0) | 10 (21.7) |
Male | 14 (56.0) | 36 (78.3) |
ECOG PS, n (%) | ||
0 | 21 (84.0) | 26 (56.5) |
1 | 4 (16.0) | 20 (43.5) |
B symptom, n (%) | ||
Yes | 1 (4.0) | 9 (19.6) |
No | 24 (96.0) | 37 (80.4) |
Ann-Arbor stage n (%) | ||
I/II | 1 (4.0) | 8 (17.4) |
III/IV | 24 (96.0) | 38 (82.6) |
LDH expression, n (%) | ||
LDH ≤ 240 | 14 (56.0) | 29 (63.0) |
LDH>240 | 11 (44.0) | 17 (37.0) |
Prior PD-(L)1 treatment, n (%) | ||
Yes | 13 (52.0) | 41 (89.1) |
No | 12 (48.0) | 5 (10.9) |
Prior treatment line | ||
Median (min-max) | 4 (1-9) | 3 (1–12) |
Lymphoma subtypes, n (%) | ||
Follicular lymphoma | 8 (32.0) | 1 (2.2) |
Classical Hodgkin lymphoma | 9 (36.0) | 42 (91.3) |
Peripheral T-cell lymphoma | 2 (8.0) | 3 (6.5) |
Diffuse large B-cell lymphoma | 6 (24.0) | 0 |
Prior treatment for Classical Hodgkin lymphoma | ||
ASCT | 2 (22.2) | 11 (26.2) |
BV | 0 | 5 (11.9) |
Anti-CD30 ADC investigation | 4 (44.4) | 6 (14.3) |
PD-(L)1 blockade | 9 (100) | 41 (97.6) |
PD-1 | 8 (88.9) | 38 (90.5) |
PD-L1 | 1 (11.1) | 8 (19.0) |
Anti–PD-1–based regimen as their most recent therapy | 4 (44.4) | 28 (66.7) |
Refractory (PD during treatment or within 3 months after the last dose) | 9 (100) | 34 (81.0) |
One line of prior PD-(L)1 blockade | 5 (55.6) | 20 (47.6) |
PD-(L)1 monotherapy | 5 (55.6) | 14 (33.3) |
PD-(L)1 combination therapy | 0 | 6 (14.3) |
Two or more lines of prior PD-(L)1 blockade | 4 (44.4) | 21 (50.0) |
Prior treatment line for Classical Hodgkin lymphoma | ||
Median (Min-max) | 6.0 (3–9) | 3.5 (2–12) |
